Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
Gut
|
December 14, 2004
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
E V Loftus, G C Harewood, C G Loftus, et al.
The American Journal of Gastroenterology
|
July 14, 2000
Early measles virus infection is associated with the development of inflammatory bowel disease
D S Pardi, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
August 13, 2015
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease
S Singh, N S Ding, K L Mathis, et al.
Gut
|
May 2, 2006
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein
J F Colombel, C A Solem, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 12, 2013
Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease
S V Kane, B Neis, B D Becker, et al.
Digestive Diseases and Sciences
|
March 19, 2024
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
L Peyrin-Biroulet, P Bossuyt, D Bettenworth, et al.
Gut
|
October 16, 2001
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
P W Lowry, C L Franklin, A L Weaver, et al.
Inflammatory Bowel Diseases
|
March 16, 2012
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience
S V Kane, S Horst, W J Sandborn, et al.
Inflammatory Bowel Diseases
|
August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
W J Sandborn, E V Loftus, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics
|
June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
W J Sandborn, B E Sands, D C Wolf, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
Gut
|
December 14, 2004
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
E V Loftus, G C Harewood, C G Loftus, et al.
The American Journal of Gastroenterology
|
July 14, 2000
Early measles virus infection is associated with the development of inflammatory bowel disease
D S Pardi, W J Tremaine, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
August 13, 2015
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease
S Singh, N S Ding, K L Mathis, et al.
Gut
|
May 2, 2006
Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein
J F Colombel, C A Solem, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 12, 2013
Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease
S V Kane, B Neis, B D Becker, et al.
Digestive Diseases and Sciences
|
March 19, 2024
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
L Peyrin-Biroulet, P Bossuyt, D Bettenworth, et al.
Gut
|
October 16, 2001
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
P W Lowry, C L Franklin, A L Weaver, et al.
Inflammatory Bowel Diseases
|
March 16, 2012
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience
S V Kane, S Horst, W J Sandborn, et al.
Inflammatory Bowel Diseases
|
August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
W J Sandborn, E V Loftus, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics
|
June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
W J Sandborn, B E Sands, D C Wolf, et al.
Page
of 8